Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
At close: 05:29PM CET
| Previous close | 180.50 |
| Open | 180.05 |
| Bid | 183.60 x 0 |
| Ask | 183.70 x 0 |
| Day's range | 180.00 - 184.00 |
| 52-week range | 127.10 - 245.40 |
| Volume | |
| Avg. volume | 741,833 |
| Market cap | 54.159B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 18.56 |
| EPS (TTM) | 9.89 |
| Earnings date | 10 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 200.50 |
- PR Newswire
Kineret® (anakinra) receives positive opinion from the CHMP for treatment of patients with COVID-19 pneumonia
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of Kineret® (anakinra) for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminoge
- Zacks
Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug
The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.
- PR Newswire
Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
The first targeted C3 therapy approved in the EU
© 2022 Yahoo. All rights reserved.
